2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-148032
    5-Benzyloxytryptamine 20776-45-8 98%
    5-Benzyloxytryptamine (5-BT) is a selective partial agonist for 5-hydroxytryptamine 1D/1B (5-HT1D/1B) receptors with an IC50 value of 40 nM for bovine caudate 5-HT1D and reduced affinity for other receptors (5-HT2 IC50>470 nM). 5-Benzyloxytryptamine inhibits adenylate cyclase to decrease neurotransmitter release and downregulate cAMP signaling. 5-Benzyloxytryptamine is promising for research of neurotransmitter imbalance-related disorders like migraine.
    5-Benzyloxytryptamine
  • HY-148038
    5-HT3 antagonist 5 901599-43-7 99.75%
    5-HT3 antagonist 5 is a quinoxalin-2-carboxamide compound, a 5-HT3 receptor antagonist. 5-HT3 antagonist 5 exerts antagonism on 5-HT3 agonist and 2-methyl-5-HT, and shows anti-depressant effect in mice.
    5-HT3 antagonist 5
  • HY-148108
    AChE-IN-27 177028-90-9 98.27%
    AChE-IN-27 (compound 8c) is an AChE inhibitor (IC50=0.19 µM). AChE-IN-27 can be used in studies of neurological diseases such as alzheimer's disease, dementia, ataxia and myasthenia gravis.
    AChE-IN-27
  • HY-148133
    GSK-3β inhibitor 12 784170-07-6 99.81%
    GSK-3β inhibitor 12 (compound 15) is an inhibitor of GSK-3β. GSK-3β inhibitor 12 inhibits 49.11% and 37.11% activity of 25 μM and 50 μM GSK-3β, respectively. GSK-3β inhibitor 12 can be used for the research of neurodegenerative diseases.
    GSK-3β inhibitor 12
  • HY-148145
    Mebanazine 65-64-5 98%
    Mebanazine is a potent monoamine oxidase (MAO) inhibitor. Mebanazine can be used in research of depression.
    Mebanazine
  • HY-148146
    Phenoxypropazine 3818-37-9 98%
    Phenoxypropazine is a potent monoamine oxidase (MAO) inhibitor. Phenoxypropazine can be used in research of depression.
    Phenoxypropazine
  • HY-148156
    Hydroxydione 303-01-5 98%
    Hydroxydione has an effect of general anesthetic. Hydroxydione is a neuroactive steroid it can be used for anaesthesia related research.
    Hydroxydione
  • HY-148158
    Pivalylbenzhydrazine 306-19-4 98%
    Pivalylbenzhydrazine (Pivhydrazine) is a potent monoamine oxidase (MAO) inhibitor. Pivalylbenzhydrazine decreases cartilage growth in normal rats. Pivalylbenzhydrazine can be used in research of depression.
    Pivalylbenzhydrazine
  • HY-148159
    Safrazine 33419-68-0 98%
    Safrazine is an irreversible, non-specific and orally active monoamine oxidase (MAO) inhibitor. Safrazine can be used for the research of depression.
    Safrazine
  • HY-148165
    L-Cytidine 26524-60-7 ≥98.0%
    L-Cytidine is an L-configurational form of Cytidine (HY-B0158). L-Cytidine is a pyrimidine nucleoside, a component of RNA. Cytidine can control the glial glutamate cycle, affect brain phospholipid metabolism, catecholamine synthesis and mitochondrial function.
    L-Cytidine
  • HY-148240
    JNJ-65355394 2230598-99-7 98%
    JNJ-65355394 (Compound 28) is an O-GlcNAc hydrolase (OGA) inhibitor.
    JNJ-65355394
  • HY-148250
    TP-050 98%
    TP-050 is a potent, orally active and selective NMDAR agonist with an EC50 value of 0.51 µM and 9.6 µM for GluN2A and GluN2D, respecticely. TP-050 can cross the blood-brain barrier (BBB). TP-050 induces hippocampal long-term (LPT) potentiation enhancemen and enhances neuronal signal transmission.
    TP-050
  • HY-148253
    TP-030-1 2095514-75-1 98%
    TP-030-1 is an inhibitor of RIPK1. TP-030-1 inhibits hRIPK1 with a Ki value of 3.9 nM and inhibits mRIPK1 with an IC50 value of 4.2 μM. TP-030-1 can be used for the research of inflammatory diseases and neurodegenerative diseases.
    TP-030-1
  • HY-14827A
    Zicronapine fumarate 170381-17-6 98%
    Zicronapine (Lu 31-130) fumarate is an antipsychotic medication with a strong pro-cognitive effect in animal models and the potential to treat a number of neurological and psychiatric diseases. Zicronapine (Lu 31-130) fumarate has potent antagonistic effects at dopamine D1/D2, and serotonin 5-HT2A receptors.
    Zicronapine fumarate
  • HY-148306
    γ-Secretase modulator 14 1420200-85-6 98%
    γ-Secretase modulator 14 is a γ-secretase modulator. γ-Secretase modulator 14 has the potenial for Alzheimer's disease (AD) research (WO2013010904A1; compound 42).
    γ-Secretase modulator 14
  • HY-148312
    Sirtuin modulator 4 327104-77-8 98%
    Sirtuin modulator 4 (compound 12) is a sirtuin modulator. Sirtuin modulator 4 shows inhibitory effect to SIRT1 with an EC50 value of 51-100 μM. Sirtuin modulator 4 may be used for the research of increasing the lifespan of a cell, and preventing a wide variety of diseases and disorders including, for example, diabetes, obesity, neurodegenerative diseases, cardiovascular diseases, inflammation and cancer.
    Sirtuin modulator 4
  • HY-148322
    Sirtuin modulator 5 694469-31-3 98%
    Sirtuin modulator 5 is a sirtuin modulating agent. Sirtuin modulator 5 can activate SIRT1 with a DC50 value of <50 μM. Sirtuin modulator 5 can be used for increasing the lifespan of a cell and used for the research of variety of diseases including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity.
    Sirtuin modulator 5
  • HY-148331
    Z-Thioprolyl-Thioproline 118059-40-8 98%
    Z-Thioprolyl-Thioproline is a bovine brain prolyl endopeptidase (PEP) inhibitor (IC50=16 µM; Ki=37 µM). Z-Thioprolyl-Thioproline is used in the study of neurological disorders such as memory disorders and cognitive disorders.
    Z-Thioprolyl-Thioproline
  • HY-148332
    Z-Thioprolyl-Thiazolidine 118059-38-4 98%
    Z-Thioprolyl-Thiazolidine is a potent and specific prolyl endopeptidase inhibitor with an Ki value of 0.36 nM for bovine brain prolyl endopeptidase
    Z-Thioprolyl-Thiazolidine
  • HY-148353
    PF-06455943 1527474-15-2 98%
    PF-06455943 is a leucine rich repeat kinase 2 (LRRK2) inhibitor with IC50 value of 3 nM. PF-06455943 also is a PET radioligand. PF-06455943 can be used for the research of ADME/neuro PK characterization and Parkinson disease (PD).
    PF-06455943
Cat. No. Product Name / Synonyms Application Reactivity